ADRIATIC

一行要約

Limited-stage SCLC (LS-SCLC) の化学放射線療法 (CRT) 後 consolidation における Durvalumab +/- Tremelimumab vs Placebo の phase III。Durvalumab 群で OS HR 0.73 (median NR vs 33.4 mo) を示し、LS-SCLC の CRT 後 IO consolidation として初の positive trial。PACIFIC モデルの SCLC 版。

試験デザイン

• 対象: LS-SCLC、concurrent CRT (4 cycles EP + thoracic RT) 後に CR/PR/SD、N=730 (1:1:1 の 3 群)
• 介入群 A (n=264) : Durvalumab 1500mg IV q4w (最大 24 mo)
• 介入群 B (n=200) : Durvalumab 1500mg + Tremelimumab 75mg IV q4w (4 cycles) → Durvalumab maintenance
• 対照群 (n=266) : Placebo IV q4w
• 層別化: Stage (I-II vs III)、ECOG PS (0 vs 1)、PCI 実施有無
• Dual primary: Durvalumab (群 A) vs Placebo の OS および PFS

主要結果

• OS (Durvalumab vs Placebo, primary) : HR 0.73 (95% CI 0.57–0.93, p=0.0104)、median NR vs 33.4 mo。24 mo OS rate: 68.4% vs 58.4%
• PFS (Durvalumab vs Placebo) : HR 0.76 (95% CI 0.61–0.95)、median 16.6 vs 9.2 mo
• Durvalumab + Tremelimumab 群: OS HR 0.75 (nominal、formal testing hierarchy 外)。Tremelimumab 追加の incremental benefit は明確でない
• ORR: CRT 後の consolidation のため「奏効維持」が主な指標
• 安全性: Grade 3-4 irAE: Durvalumab 9.3% vs Placebo 3.4%。肺臓炎 (全 grade 17.2% vs 10.2%)、甲状腺機能障害が主な irAE

臨床的意義

• LS-SCLC 治療の 30 年ぶりの進歩: LS-SCLC は CRT+PCI 以降 30 年間 standard 変化なし。ADRIATIC は IO consolidation で初めて OS 改善を達成
• PACIFIC パラダイムの SCLC 展開: Stage III NSCLC における CRT 後 Durvalumab consolidation (PACIFIC) の成功モデルを SCLC に適用
• PCI との関係: PCI 実施/非実施がサブグループ解析で検討されており、IO 時代の PCI 必要性再評価に寄与
• ES-SCLC IO (IMpower133 / CASPIAN) との統合: LS + ES の両 stage で IO が standard 化し、SCLC 全体に IO が浸透

Open Questions

• Tremelimumab 追加の意義: Durvalumab 単独 vs Durvalumab+Tremelimumab の差が小さく、CTLA-4 併用の LS-SCLC における役割は不明
• PCI の再評価: IO consolidation 時代に PCI が依然必要か、brain MRI surveillance で代替可能か
• SCLC-molecular-subtypes と IO 感受性: LS-SCLC における subtype 分布と Durvalumab benefit の関係
• Biomarker: LS-SCLC で PD-L1/TMB/SCLC subtype のいずれかが IO benefit を predict するか

重要論文 Top 10

1. ★★★★★ Cheng et al. NEnglJMed 2024 — ADRIATIC primary publication、OS HR 0.73
2. Faivre-Finn et al. — ADRIATIC PFS analysis and subgroup data
3. ★★★★★ Antonia et al. NEnglJMed 2018 — PACIFIC—CRT 後 IO consolidation の original paradigm
4. ★★★★ Takahashi et al. LancetOncol 2017 — LS-SCLC CRT の日本標準 (concurrent/sequential RT meta-analysis 文脈)
5. ★★★★★ Horn et al. NEnglJMed 2018 — IMpower133—ES-SCLC IO、SCLC IO landscape の先行試験

関連エンティティ・概念

• PD-L1-inhibitor — Durvalumab
• CTLA-4-inhibitor — Tremelimumab
• PACIFIC — CRT 後 IO consolidation の paradigm (NSCLC)
• IMpower133 / CASPIAN — ES-SCLC IO
• SCLC-molecular-subtypes — IO 感受性の molecular basis
• KEYNOTE-604 — ES-SCLC における Pembrolizumab+EP

関連論文

Clinical-NEC

• Eba et al. JpnJClinOncol 2014 — A phase III trial comparing irinotecan and cisplatin with etoposide and cisplatin in adjuvant chemotherapy for
• Sen et al. LancetOncol 2025 — Pulmonary neuroendocrine neoplasms the molecular landscape, therapeutic challenges, and diagnosis and management

Clinical-NSCLC-Driver negative

• Li et al. FrontImmunol 2026 — The application and challenges of immune checkpoint inhibitors in lung cancer therapy

Clinical-NSCLC-Driver-Other

• Johnson et al. JClinOncol 2014 — Recent clinical advances in lung cancer management

Clinical-SCLC

• Doshita et al. AdvRadiatOncol 2023 — Incidence and treatment outcome of radiation pneumonitis in patients with limited-stage small cell lung cancer treated
• Amini et al. Cancer 2014 — Progress in the management of LD-SCLC
• Pijls-Johannesma et al. CancerTreatRev 2007 — Timing of chest radiotherapy in patients with limited stage small cell lung cancer a systematic review and
• Lad et al. Chest 1994 — A prospective randomized trial to determine the benefit of surgical resection of residual disease following response of
• Dai et al. CurrTreatOptionsOncol 2026 — Addressing unmet needs in the management of small cell lung cancer treatment of brain metastases, quality of life, and
• Bonanno et al. EurJCancer 2018 — The role of immune microenvironment in small-cell lung cancer distribution of PD-L1 expression and prognostic role of
• Li et al. JCOGlobOncol 2025 — Durvalumab in limited-stage small cell lung cancer clinical triumph and toward sustainable value
• Koletsis et al. JCardiothoracSurg 2009 — Current role of surgery in small cell lung carcinoma
• Warde et al. JClinOncol 1992 — Does thoracic irradiation improve survival and local control in limited-stage small-cell carcinoma of the lung A
• Gregor et al. JClinOncol 1997 — Randomized trial of alternating versus sequential radiotherapychemotherapy in limited-disease patients with small-cell
• Spiro et al. JClinOncol 2006 — Early compared with late radiotherapy in combined modality treatment for limited disease small-cell lung cancer a
• Cheng et al. NEnglJMed 2024 — Durvalumab after chemoradiotherapy in limited-stage small-cell lung cancer
• Rudin et al. NatRevDisPrimers 2021 — Small-cell lung cancer
• Zhao et al. SignalTransductTargetTher 2026 — Sintilimab plus concurrent chemoradiotherapy for treatment of locally advanced small cell lung cancer (SINCE-01) a